Huntington's Disease
Familial Amyotrophic Lateral Sclerosis
Spinal Muscular Atrophy
Spinocerebellar Ataxia
Early-onset Familial Alzheimer’s Disease
Parkinson's Disease
Progressive Supranuclear Palsy
Dravet Syndrome
Angelman Syndrome
Friedrich Ataxia
Batten Disease
science
CRISPR by Design™
Scribe is building and applying a suite of CRISPR technologies into a single continually evolving and expanding genetic modification platform.
We are rapidly generating hundreds of synthetic CRISPR molecules and novel technologies every month and folding the best into a fully integrated set of genome editing modalities.
X-editing (XE) technology is our first engineered molecule built holistically on a novel CRISPR foundation to provide three key attributes needed for therapeutic use and in vivo genetic modification: greater activity, specificity and deliverability.
partner
with us
Join us in engineering next-generation CRISPR-based genetic medicines.
Partner
targets
Engineering genetic medicine
Scribe is rapidly working to end genetic disease using the near limitless power of engineered CRISPR technologies that will allow us and our partners to move quickly from the lab into the clinic.
As our engineering core continues to evolve and expand, we will utilize XE to address diseases of significant unmet medical need.
Neurological Diseases
Ophthalmological Disease
Retinitis Pigmentosa
Cone-rod Dystrophy
Leber's Congenital Amaurosis
Hereditary Optic Atrophy
Stargardt Macular Degeneration
Choroideremia
Glaucoma
Best Vitelliform Macular Dystrophy
Achromatopsia
Usher Syndrome
Cone-rod Dystrophy
Leber's Congenital Amaurosis
Hereditary Optic Atrophy
Stargardt Macular Degeneration
Choroideremia
Glaucoma
Best Vitelliform Macular Dystrophy
Achromatopsia
Usher Syndrome
Multisystem, Muscle & Metabolic
Cystic Fibrosis
Duchenne Muscular Dystrophy
Myotonic Dystrophy
Limb-girdle Muscular Dystrophy
TTR Amyloidosis
Alpha-1 Antitrypsin Deficiency
Familial Hypercholesterolemia
Tyrosinemia
Phenylketonuria
Acute Intermittent Porphyria
Hypertriglyceridemia
Hutchinson–Gilford Progeria Syndrome
Methylmalonic Acidemia
Propionic Acidemia
Primary Hyperoxaluria
Duchenne Muscular Dystrophy
Myotonic Dystrophy
Limb-girdle Muscular Dystrophy
TTR Amyloidosis
Alpha-1 Antitrypsin Deficiency
Familial Hypercholesterolemia
Tyrosinemia
Phenylketonuria
Acute Intermittent Porphyria
Hypertriglyceridemia
Hutchinson–Gilford Progeria Syndrome
Methylmalonic Acidemia
Propionic Acidemia
Primary Hyperoxaluria
Hematopoietic Disorders
Sickle Cell Disease
Severe Combined Immunodeficiency
Fanconi Anemia
Hemophilia A/B
Chronic Granulomatous Disease
Von Willebrand Disease
Severe Combined Immunodeficiency
Fanconi Anemia
Hemophilia A/B
Chronic Granulomatous Disease
Von Willebrand Disease
Cell Therapy
Modifications can be made to nearly any cell therapy product including but not limited to:
CAR-T
NK
TiL
HSC
iPSC
CAR-T
NK
TiL
HSC
iPSC
publications
scribe
v. to mark or score materials with a pointed instrument as a guide to cutting or assembling
Scribe is designing custom tools for therapeutic use on any given genetic target or application in vivo.